Eli Lilly Predicts Robust Revenue Growth, Eyes $58-61 Billion by 2025

Eli Lilly and Company forecasts a significant revenue increase to $58-61 billion by 2025, driven by strong sales of its diabetes and obesity treatments, Mounjaro and Zepbound. CEO ...